EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 806 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 The Future Front Line: Pre-Med During COVID-19 September 8, 2020 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma May 23, 2023 Load more HOT NEWS Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma
